Archives of neurology · 2006
Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir.
Клиническое исследование I фазыКлиническое исследование II фазыСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quan Dianna, Hammack Barbara N, Kittelson John, Gilden Donald H
Аннотация
BACKGROUND: Postherpetic neuralgia (PHN) is a complication of shingles (herpes zoster), a painful rash due to varicella-zoster virus reactivation. Studies of patients with PHN and zoster sine herpete (radicular pain without rash) support the notion that low-grade viral ganglionitis contributes to pain. If chronic pain reflects active infection, then antiviral therapy may help patients with PHN.
OBJECTIVE: To determine whether antiviral treatment helps reduce PHN-associated pain.
DESIGN: Prospective, open-label phase I/II clinical trial.
SETTING: Tertiary care university hospital.
PATIENTS: Fifteen patients with moderate to severe PHN.
INTERVENTIONS: Intravenous acyclovir at a dosage of 10 mg/kg every 8 hours for 14 days followed by oral valacyclovir at a dosage of 1000 mg 3 times per day for 1 month.
MAIN OUTCOME MEASURE: Numeric Rating Scale for Pain score.
RESULTS: As defined by a decrease of 2 or more points on the Numeric Rating Scale for Pain, 8 (53%) of 15 patients reported improvement.
CONCLUSION: Clinical improvement reported by most of our patients warrants further investigation in a larger, randomized, double-blind, placebo-controlled trial.
OBJECTIVE: To determine whether antiviral treatment helps reduce PHN-associated pain.
DESIGN: Prospective, open-label phase I/II clinical trial.
SETTING: Tertiary care university hospital.
PATIENTS: Fifteen patients with moderate to severe PHN.
INTERVENTIONS: Intravenous acyclovir at a dosage of 10 mg/kg every 8 hours for 14 days followed by oral valacyclovir at a dosage of 1000 mg 3 times per day for 1 month.
MAIN OUTCOME MEASURE: Numeric Rating Scale for Pain score.
RESULTS: As defined by a decrease of 2 or more points on the Numeric Rating Scale for Pain, 8 (53%) of 15 patients reported improvement.
CONCLUSION: Clinical improvement reported by most of our patients warrants further investigation in a larger, randomized, double-blind, placebo-controlled trial.